New Trial Data Confirm Clinical Effectiveness With NeuroStar TMS Therapy

Neuronetics sponsored an observational study of patients in the “real world” which confirms the clinical effectiveness and adherence rates of patients with Major Depressive Disorder (MDD) treated with the NeuroStar TMS Therapy system. This data continues to support the premise that patients with MDD who do not find relief with medication or who are unable to tolerate the medicines side effects have an effective, proven non-invasive and non-systemic  alternative.

“These data add to the impressive body of evidence that support the positive impact that TMS Therapy may have on patients living with major depression,” said Karl Lanocha, M.D., Medical Director of The TMS Center of New England, regarding the Neuronetics study.

The results of this study was released at the American Psychiatric Association meeting on May 15, 2011 in Hawaii.

The TMS Center of Colorado, LLC has been providing TMS therapy in Denver, Colorado since 2009. We serve the entire Rocky Mountain region including the front range communities; Colorado Springs, Boulder, Loveland, Fort Collins,  Longmont, Greeley, Denver as well as mountain communities such as Aspen, Vail and Steamboat Springs. We have also had patients from Wyoming, Montana and Missouri.

In addition to treating MDD, we are interested in the use of TMS for such off-label conditions as chronic pain, tinnitus, auditory hallucinations and Parkisons disease.

Tags: , , , , , , , ,

This entry was posted on Tuesday, July 26th, 2011 and is filed under TMS Health. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

TMS Center of Colorado Makes KCNC News in Denver

Major Depressive Disorder (MDD) affects up to 50 million people in the USA. The affects of the disease on the person with MDD, their family and co-workers/employers can be devastating.  Time away from family and activities, lost work days and productivity, and side affects of  conventional treatment are some of the costs associated with MDD.  There is a relatively new treatment for MDD which was described in a television news segment which aired on March 22, 2011 on KCNC, Channel 4 in Denver.

This treatment is Transcranial Magnetic Stimulation TMS or rTMS).  NeuroStar TMS therapy is a FDA cleared treatment for major depressive disorder. TMS has also been used clinically in off label treatment and in clinical research to treat a wide variety of other neuorlogical and neuro-psychiatric conditions, including: chronic pain, post traumatic stress disorder (PTSD), phantom limb pain, depression associated with Parkinson’s Disease, post partum depression, tinnitus, auditory halucinations, and other conditions.

The NeuroStar TMS therapy system has been available in Colorado since November 2009 through the TMS Center of Colorado, LLC, located in Denver. This center was the first in Colorado (and the Rocky Mountain Region) to treat patients using this state of the art technology. There is hope for those suffering from MDD and other conditions.

Watch KCNC Coverage

Tags: , , , , , , , , , , , , ,

This entry was posted on Friday, March 25th, 2011 and is filed under News and Events, TMS Health. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Innovations in Healthcare

2009 is coming to a close. The healthcare debate continues as does one of the primary reasons blamed for the explosion of healthcare costs; innovations in healthcare. CNN has just issued its top ten health innovations for 2009 (http://edition.cnn.com/2009/HEALTH/12/14/top.health.innovations.2009/), 5th on the list repetitive Transcranial Magnetic Stimulation. This treatment is now available in 31 states and the demand is growing. Research continues to generate potential new uses for this device as well. Current diagnosis/conditions being studied for rTMS therapy are Parkinson’s disease, depression, tinnitus, stroke, chronic pain, migraines……….and the list goes on. With mild side effects this non-systemic, non-invasive therapy has minimal downside beyond the expense and limited third party reimbursement. The limited third party reimbursement places responsibility on the consumer for demanding access to this innovative, FDA cleared therapy. The costs of healthcare rise and innovation is in part to blame but we should be very happy about innovation and the improved quality of life it can bring.

Tags: , , , , , , , , , , , , , , , ,

This entry was posted on Saturday, December 26th, 2009 and is filed under TMS Health. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.